Literature DB >> 11246660

Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years.

I M Gilboe1, T K Kvien, G Husby.   

Abstract

OBJECTIVE: To examine changes in health status, disease activity, and organ damage after 2 years and to study possible disease variables predicting change in health status, disease activity, and organ damage at followup in systemic lupus erythematosus (SLE). Second, to compare changes in health status in patients with SLE to that of matched patients with rheumatoid arthritis (RA) and matched healthy controls.
METHODS: A 2 year longitudinal observational study, measuring health status (Short-Form 36. visual analog scale for pain and fatigue, modified Health Assessment Questionnaire, patient global assessment of disease activity), disease activity, and organ damage in 87 patients with SLE. Health status measures in SLE were compared to 65 matched RA patients selected from the Oslo RA register and to 77 matched healthy controls from the population register.
RESULTS: On a group level the SLE patients showed stable health status measures and disease activity scores 2 years after baseline, but organ damage scores increased significantly. Increase in organ damage was significantly and independently predicted by baseline scores of disease activity and organ damage, health status, and disease activity by the respective baseline scores. Changes in health status measures over 2 years were similar in SLE, RA, and healthy controls.
CONCLUSION: Our 2 year longitudinal observational SLE study showed a stable course of health status and disease activity, whereas organ damage increased. Disease activity and organ damage at baseline predicted the latter. Our results indicate the value of careful monitoring of disease activity over time in SLE and individually tailored treatment guided by the predictors of course and outcome.

Entities:  

Mesh:

Year:  2001        PMID: 11246660

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment.

Authors:  C Fiehn; Y Hajjar; K Mueller; R Waldherr; A D Ho; K Andrassy
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

2.  The Effectiveness of Mindfulness-based Cognitive Therapy on Psychological Symptoms and Quality of Life in Systemic Lupus Erythematosus Patients: 
A Randomized Controlled Trial.

Authors:  Kamal Solati; Mohammad Mousavi; Soleiman Kheiri; Ali Hasanpour-Dehkordi
Journal:  Oman Med J       Date:  2017-09

3.  Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.

Authors:  Sawsan J Hayat; Sukhbir S Uppal; M R Narayanan Nampoory; Kaivilayil V Johny; Ramkumar Gupta; Mohammed Al-Oun
Journal:  Clin Rheumatol       Date:  2006-03-25       Impact factor: 3.650

4.  Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations.

Authors:  Lilianna Kulczycka; Anna Sysa-Jedrzejowska; Ewa Robak
Journal:  Clin Rheumatol       Date:  2010-06-09       Impact factor: 2.980

5.  Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).

Authors:  Benjamin Chaigne; Carlo Chizzolini; Thomas Perneger; Marten Trendelenburg; Uyen Huynh-Do; Eric Dayer; Thomas Stoll; Johannes von Kempis; Camillo Ribi
Journal:  BMC Immunol       Date:  2017-03-28       Impact factor: 3.615

6.  Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.

Authors:  Vibeke Strand; Pamela Berry; Xiwu Lin; Yumi Asukai; Rajesh Punwaney; Sulabha Ramachandran
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04-29       Impact factor: 4.794

7.  Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus.

Authors:  Mathilda Björk; Örjan Dahlström; Jonas Wetterö; Christopher Sjöwall
Journal:  BMC Musculoskelet Disord       Date:  2015-08-12       Impact factor: 2.362

8.  Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort.

Authors:  Julie E Davidson; Qinggong Fu; Sapna Rao; Laurence S Magder; Michelle Petri
Journal:  Lupus Sci Med       Date:  2018-05-14

9.  Factors associated with self-reported capacity to walk, jog and run in individuals with systemic lupus erythematosus.

Authors:  Gizem İrem Kinikli; Susanne Pettersson; Sevilay Karahan; Iva Gunnarsson; Elisabet Svenungsson; Carina Boström
Journal:  Arch Rheumatol       Date:  2020-12-10       Impact factor: 1.472

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.